CD8A and neoplasm: FACS analysis of treated tumors revealed a marked reduction in intratumoral Tregs and an increase in CD8+ T cells, enhancing the CD8+ T cell/Treg ratio and amplifying anti-tumor immunity in Strategy 3 compared to other strategies (Fig. 6G-M).